VANDA PHARMACEUTICALS INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits
VANDA PHARMACEUTICALS INC. (VNDA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits of $3.31 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits · last filed 2026-02-12
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $3.31M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $3.61M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $4.19M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits $4.93M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits |
|---|---|
| 2025-12-31 | $3.31M 10-K · filed 2026-02-12 |
| 2024-12-31 | $3.61M 10-K · filed 2026-02-12 |
| 2023-12-31 | $4.19M 10-K · filed 2025-02-14 |
| 2022-12-31 | $4.93M 10-K · filed 2024-02-08 |
| 2021-12-31 | $4.85M 10-K · filed 2023-02-09 |
| 2020-12-31 | $4.65M 10-K · filed 2022-02-24 |
| 2019-12-31 | $5.30M 10-K · filed 2021-02-11 |
| 2018-12-31 | $5.20M 10-K · filed 2020-02-26 |
| 2017-12-31 | $5.38M 10-K · filed 2019-02-19 |
| 2016-12-31 | $12.44M 10-K · filed 2018-02-15 |
| 2015-12-31 | $12.92M 10-K · filed 2017-02-17 |
| 2014-12-31 | $17.16M 10-K · filed 2016-02-12 |
| 2013-12-31 | $17.63M 10-K · filed 2015-03-13 |
| 2012-12-31 | $17.35M 10-K · filed 2014-02-25 |
| 2011-12-31 | $15.90M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |